{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:57:53Z","timestamp":1793847473341,"version":"4.6.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ygyno.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T06:13:28Z","timestamp":1625638408000},"page":"661-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer"],"prefix":"10.1016","volume":"162","author":[{"given":"Carolyn N.","family":"Krasner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana M.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantay L.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan R.","family":"Chadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis A.","family":"Konstantinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella M.","family":"D'Ascanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2021.07.002_bb0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ygyno.2021.07.002_bb0010","first-page":"111","article-title":"Surgical debulking of ovarian cancer: what difference does it make?","volume":"3","author":"Schorge","year":"2010","journal-title":"Rev. Obstet. Gynecol."},{"issue":"10177","key":"10.1016\/j.ygyno.2021.07.002_bb0015","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2021.07.002_bb0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40471-017-0115-y","article-title":"Challenges and opportunities in studying the epidemiology of ovarian cancer subtypes","volume":"4","author":"Doherty","year":"2017","journal-title":"Curr. Epidemiol. Rep."},{"issue":"14","key":"10.1016\/j.ygyno.2021.07.002_bb0025","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1073\/pnas.1603018113","article-title":"CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing","volume":"113","author":"Clark","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.ygyno.2021.07.002_bb0030","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2174\/0929867311320120006","article-title":"Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug","volume":"20","author":"Beretta","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"11","key":"10.1016\/j.ygyno.2021.07.002_bb0035","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1158\/0008-5472.CAN-04-3332","article-title":"Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells","volume":"65","author":"Beppu","year":"2005","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2021.07.002_bb0040","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s10637-012-9921-8","article-title":"First-in-human phase 1\/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies","volume":"31","author":"Weiss","year":"2013","journal-title":"Investig. New Drugs"},{"issue":"2","key":"10.1016\/j.ygyno.2021.07.002_bb0045","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"13","key":"10.1016\/j.ygyno.2021.07.002_bb0050","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.07.002_bb0055","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/annonc\/mdw188","article-title":"Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial","volume":"27","author":"Keefe","year":"2016","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2021.07.002_bb0060","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1200\/JCO.2003.09.072","article-title":"Therapy-related acute promyelocytic leukemia","volume":"21","author":"Beaumont","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2021.07.002_bb0065","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa042715","article-title":"DNA topoisomerase II in therapy-related acute promyelocytic leukemia","volume":"352","author":"Mistry","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2021.07.002_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.08.012","article-title":"FDA ovarian cancer clinical trial endpoints workshop: a Society of Gynecologic Oncology White Paper","volume":"147","author":"Herzog","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2021.07.002_bb0075","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2021.07.002_bb0080","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/annonc\/mdx493","article-title":"A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma","volume":"28","author":"Voss","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.07.002_bb0085","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ygyno.2020.12.025","article-title":"A phase Ib\/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer","volume":"160","author":"Duska","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.07.002_bb0090","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/1097-0142(20010901)92:5<1156::AID-CNCR1434>3.0.CO;2-G","article-title":"A phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Mullerian tumors","volume":"92","author":"Penson","year":"2001","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821005321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821005321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:38Z","timestamp":1758772718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821005321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0090825821005321"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}